Results 81 to 90 of about 412,873 (280)

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova   +5 more
wiley   +1 more source

Laser treatment in diabetic retinopathy [PDF]

open access: yes, 2007
Diabetic retinopathy is a leading cause of visual impairment and blindness in developed countries due to macular edema and proliferative diabetic retinopathy (PDR). For both complications laser treatment may offer proven therapy: the Diabetic Retinopathy
Ulbig, Michael W.   +3 more
core   +1 more source

Safety outcomes of antidiabetic medications: A comprehensive review of the EU summaries of product characteristics and international clinical practice guidelines

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Information on the safety profile of antidiabetic medications is essential for informed treatment decisions in type 2 diabetes mellitus. Although this information is available in regulatory documents of individual drugs, a comprehensive overview across all approved antidiabetics is lacking.
David Liang   +5 more
wiley   +1 more source

Translational development of crisugabalin for neuropathic pain

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Crisugabalin (HSK16149) is a next‐generation α2δ ligand developed to preserve the mechanistic rationale of gabapentinoids while refining target engagement and exposure‐related tolerability constraints. We performed a translational review of molecular/structural studies, in vivo pharmacology and behavioural safety assessments, phase I clinical ...
Rafael Batista João   +5 more
wiley   +1 more source

Engineering programmable peptide hydrogels for chronic refractory wounds: A mechanism‐driven framework

open access: yesBMEMat, EarlyView.
To break the self‐perpetuating pathology of chronic wounds, we propose a mechanism‐driven engineering framework for peptide‐based hydrogels. This review elucidates a hierarchical strategy—from molecular design to intelligent, multi‐functional systems—that enables these programmable biomaterials to dynamically intervene in key pathological loops and ...
Xiaoyu Lv   +3 more
wiley   +1 more source

Tannic acid–metal biomaterials for skin repair: Principles, immune microenvironment modulation, and translational perspectives

open access: yesBMEMat, EarlyView.
Tannic acid–metal materials are emerging as versatile wound biomaterials, but their value depends on more than multifunctionality. This review maps how tannic acid alone, free metal ions, and coordinated TA–metal systems differ in design logic, immune‐microenvironment effects, and translational potential, offering a practical framework for choosing ...
Shahid Mahmood   +6 more
wiley   +1 more source

Diabetic neuropathies. Classification, clinical features, and pathophysiological basis

open access: yes, 2005
Diabetes mellitus is associated with a wide spectrum of neuropathy syndromes, ranging from a mild asymptomatic distal sensory neuropathy to a severe disabling radiculoplexus neuropathy.
Sinnreich, M (15529949)   +2 more
core  

Initiation of Gabapentin with Opioids and Risk of Respiratory Cardiovascular and Opioid‐Related Adverse Events Following Surgery for Breast Cancer

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Pain is a key determinant of quality‐of‐life following breast cancer surgery, the most common cancer operation in the United States. Gabapentinoids are frequently prescribed for pain management, yet their respiratory, cardiovascular, and opioid‐related adverse effects remain unclear.
Jyun‐Heng Lai   +12 more
wiley   +1 more source

Exposure–Response Analysis of Enfortumab Vedotin Plus Pembrolizumab as First‐Line Therapy for Locally Advanced or Metastatic Urothelial Cancer

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Enfortumab vedotin is a nectin‐4‐directed antibody–drug conjugate currently approved in combination with pembrolizumab for the first‐line treatment of locally advanced or metastatic urothelial cancer. Here we describe the exposure–response relationship between enfortumab vedotin exposures and efficacy/safety endpoints in patients who received ≥1 dose ...
Vaishali L. Chudasama   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy